Eversept Partners, LP Amicus Therapeutics, Inc. Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 08, 2023	BUY	$6.23 - $11.12 $2.98 Million - $5.32 Million	478,245 New	478,245 $5.14 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $11.12 $2.98 Million - $5.32 Million	478,245 New	478,245 $5.14 Million
Q1 2019 May 14, 2019	SELL	$10.04 - $13.92 $630,010 - $873,480	-62,750 Closed	0 $0
Q4 2018 Nov 08, 2023	SELL	$8.38 - $13.44 $142,460 - $228,480	-17,000 Reduced 21.32%	62,750 $601,000
Q4 2018 Feb 13, 2019	SELL	$8.38 - $13.44 $142,460 - $228,480	-17,000 Reduced 21.32%	62,750 $601,000
Q3 2018 Nov 08, 2023	BUY	$11.6 - $16.54 $925,100 - $1.32 Million	79,750 New	79,750 $964,000
Q3 2018 Nov 14, 2018	BUY	$11.6 - $16.54 $925,100 - $1.32 Million	79,750 New	79,750 $964,000

311

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.53B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.